Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Non-Alcoholic Fatty Liver Disease and Vascular Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver disease worldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD is cardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. Within the next few years, NAFLD will contribute considerably to the overall...
Read MoreNon-Alcoholic Fatty Liver Disease and Vascular Disease.

The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index.

Epidemiological studies focusing on the association between liver disease and atrial fibrillation show inconsistent findings. Patients with liver disease have a higher atrial fibrillation risk. A recent meta-analysis by Karn Wijarnpreecha et al. (Department of Internal Medicine, Bassett Medical Centre, Cooperstown, NY, USA), published...
Read MoreThe risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index.

Association of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis.

T. Liu et al. aimed to explore the potential link of serum vitamin D level with NAFLD. Of the 309 initially retrieved studies, 15 studies of high quality involving a total of 20 096 participants (including 7803 NAFLD patients) were included in this meta-analysis. Meta-analysis of continuous data indicated that NAFLD patients...
Read MoreAssociation of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis.

Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients.

Liver disease is common among patients infected with HIV. The proportion of deaths caused by liver-related aetiologies has increased between 8 to 10-fold in the post-antiretroviral therapy (ART) era while AIDS-related mortality has fallen more than 90-fold. NAFLD is an important contributor to this trend. Higher rates of the...
Read MoreVitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients.

Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).

Hypothyroidism has been linked to certain elements of the metabolic syndrome such as obesity and dyslipidemia which may explain its association with NAFLD. The pathogenesis of NAFLD might be partly attributed to a state of relative intra-hepatic hypothyroidism, a condition of decreased liver thyroid hormone levels. Although...
Read MoreThyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).

Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality.

Healthy diet has been recommended for NAFLD, although it is not clear whether improving diet quality can prevent mortality. ER Yoo et al. aim to assess the impact of quality of diet on NAFLD and mortality in subjects with and without NAFLD. High diet quality was inversely associated with NAFLD and was positively associated...
Read MoreDiet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality.

The molecular basis for current targets of NASH therapies.

Metabolic substrate overload, insulin resistance, lipotoxicity, endoplasmic reticulum stress, inflammasome activation, inflammation, hepatocyte death, and fibrogenesis represent a potential target area of therapy and many are now being evaluated in preclinical studies as well as phase 1, 2, and 3 clinical trials...
Read MoreThe molecular basis for current targets of NASH therapies.

Association between non-alcoholic fatty liver disease and risk of new-onset atrial fibrillation in healthy adults.

Previous studies demonstrated conflicting results regarding the association between non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF). The statistical power was not sufficient because of modest sample sizes of these studies. We analyzed a large population-based cohort to evaluate the association between NAFLD and AF...
Read MoreAssociation between non-alcoholic fatty liver disease and risk of new-onset atrial fibrillation in healthy adults.

Increased risk of low bone mineral density in patients with non-alcoholic fatty liver disease: a cohort study.

NAFLD has been suggested to be a risk factor associated with low BMD (bone mineral density) in several cross-sectional studies. This longitudinal cohort study aims to explore the effect of NAFLD and its severity on low BMD.

Read MoreIncreased risk of low bone mineral density in patients with non-alcoholic fatty liver disease: a cohort study.

A Cross-Sectional Study of the Public Health Response to NAFLD in Europe

In 2018 and 2019, NAFLD experts in 29 European countries completed an English-language survey on policies, guidelines, awareness, monitoring, diagnosis and clinical assessment in their country. The data were compiled, quality checked against existing official documents and reported descriptively...

Read MoreA Cross-Sectional Study of the Public Health Response to NAFLD in Europe

Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease.

In this study, A. Ozturk et al. (Center for Ultrasound Research & Translation, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA) evaluated the diagnostic accuracy of shear wave elastography for differentiating high-risk NASH from non-alcoholic fatty liver and low-risk NASH. One hundred sixteen adult patients underwent liver...
Read MoreDiagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease.